Senti Biosciences Inc (SNTI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Senti Biosciences Inc stock (SNTI) is currently trading at $0.88. Senti Biosciences Inc PS ratio (Price-to-Sales) is 55.46. Analyst consensus price target for SNTI is $11.50. WallStSmart rates SNTI as Sell.
- SNTI PE ratio analysis and historical PE chart
- SNTI PS ratio (Price-to-Sales) history and trend
- SNTI intrinsic value — DCF, Graham Number, EPV models
- SNTI stock price prediction 2025 2026 2027 2028 2029 2030
- SNTI fair value vs current price
- SNTI insider transactions and insider buying
- Is SNTI undervalued or overvalued?
- Senti Biosciences Inc financial analysis — revenue, earnings, cash flow
- SNTI Piotroski F-Score and Altman Z-Score
- SNTI analyst price target and Smart Rating
Senti Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Senti Biosciences Inc (SNTI) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Senti Biosciences Inc (SNTI) Key Strengths (0)
Supporting Valuation Data
Senti Biosciences Inc (SNTI) Areas to Watch (6)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 55.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Fairly priced relative to book value
Supporting Valuation Data
Senti Biosciences Inc (SNTI) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (55.46), Price/Book (2.97) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -394.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -394.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SNTI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SNTI's Price-to-Sales ratio of 55.46x trades 40% below its historical average of 93.2x (67th percentile). The current valuation is 92% below its historical high of 673.28x set in Oct 2021, and 2914% above its historical low of 1.84x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~45.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Senti Biosciences Inc (SNTI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Senti Biosciences Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 338,000 with 100% decline year-over-year.
Key Findings
Spending 3044% of revenue (10M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.13, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Senti Biosciences Inc.
Bottom Line
Senti Biosciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Senti Biosciences Inc(SNTI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Senti Biosciences Inc (SNTI) is a cutting-edge biotechnology company focused on revolutionizing synthetic biology to develop next-generation cell and gene therapies. Leveraging its proprietary GeneCircuit platform, Senti aims to create programmable therapies designed to address a variety of diseases, including cancer and genetic disorders, thus enhancing the precision of personalized medicine. With a strong development pipeline and strategic partnerships, Senti is well-positioned to lead advancements in engineered cell therapies, providing innovative solutions to address significant unmet medical needs in the biopharmaceutical landscape.